TRIAL RESULTS · SIDE EFFECTS
Dulaglutide side effects
ANSWER
In 11 placebo-controlled trials with posted results, the most common side effects of Dulaglutide were nausea 14.5% (placebo 5.5%), diarrhoea 12.8% (placebo 8.5%), nasopharyngitis 11.2% (placebo 10.4%). Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
27
with an arm on Dulaglutide, of 144 registered
Against placebo
11
placebo-controlled trials
People in those trials
6,587
on Dulaglutide · 5,907 on placebo
Read
2026-10-03
ClinicalTrials.gov
VS PLACEBO
Most common side effects, Dulaglutide beside placebo
Share of people with each side effect in 11 placebo-controlled trials with posted results: 6,587 people on Dulaglutide (all doses), 5,907 on placebo, same trials. Listed only when reported for at least half of the people on Dulaglutide. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
ALL TRIALS
The 100 most reported of 2586 side effects reported
Every trial with posted results and an arm on Dulaglutide (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Dulaglutide | Placebo | Trials |
|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | 17.2% (3,196 of 18,623) | 5.5% | 26 |
| Diarrhoea | Gastrointestinal disorders | 14.9% (2,766 of 18,576) | 8.5% | 25 |
| Vomiting | Gastrointestinal disorders | 8.1% (1,459 of 18,101) | 3.3% | 24 |
| Constipation | Gastrointestinal disorders | 8.8% (1,389 of 15,835) | 4.1% | 19 |
| Nasopharyngitis | Infections and infestations | 7.8% (1,339 of 17,208) | 10.4% | 17 |
| Decreased appetite | Metabolism and nutrition disorders | 7.8% (1,228 of 15,708) | 2.2% | 20 |
| Urinary tract infection | Infections and infestations | 7.2% (1,075 of 15,004) | 9.8% | 14 |
| Covid-19 | Infections and infestations | 13.9% (1,062 of 7,631) | 6.0% | 6 |
| Dyspepsia | Gastrointestinal disorders | 6.0% (1,016 of 16,803) | 2.8% | 19 |
| Back pain | Musculoskeletal and connective tissue disorders | 5.9% (910 of 15,297) | 7.9% | 15 |
| Hypertension | Vascular disorders | 5.2% (851 of 16,352) | 8.4% | 13 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 5.9% (826 of 13,886) | 7.6% | 11 |
| Dizziness | Nervous system disorders | 5.4% (815 of 15,012) | 5.8% | 17 |
| Cataract | Eye disorders | 5.6% (772 of 13,726) | 7.1% | 8 |
| Upper respiratory tract infection | Infections and infestations | 3.4% (514 of 15,255) | 7.9% | 16 |
| Headache | Nervous system disorders | 3.2% (505 of 15,643) | 5.8% | 20 |
| Hypoglycaemia | Metabolism and nutrition disorders | 3.1% (464 of 14,996) | 6.6% | 9 |
| Influenza | Infections and infestations | 3.1% (454 of 14,462) | 7.8% | 12 |
| Bronchitis | Infections and infestations | 2.7% (429 of 16,093) | 8.3% | 11 |
| Osteoarthritis | Musculoskeletal and connective tissue disorders | 2.4% (394 of 16,293) | 5.9% | 13 |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | 2.2% (357 of 16,462) | 0.1% | 16 |
| Pneumonia | Infections and infestations | 1.8% (309 of 16,918) | 2.9% | 14 |
| Eructation | Gastrointestinal disorders | 3.1% (281 of 8,991) | 0.0% | 10 |
| Pain in extremity | Musculoskeletal and connective tissue disorders | 2.0% (278 of 13,868) | 4.8% | 8 |
| Cough | Respiratory, thoracic and mediastinal disorders | 3.7% (272 of 7,321) | 5.0% | 9 |
| Asthenia | General disorders | 1.7% (240 of 13,865) | 0.1% | 10 |
| Hyperglycaemia | Metabolism and nutrition disorders | 1.6% (234 of 14,487) | 6.4% | 12 |
| Microalbuminuria | Renal and urinary disorders | 4.1% (232 of 5,602) | 5.1% | 3 |
| Hypotension | Vascular disorders | 1.6% (210 of 12,953) | 0.1% | 6 |
| Benign prostatic hyperplasia | Reproductive system and breast disorders | 2.0% (168 of 8,588) | 4.9% | 8 |
| Acute kidney injury | Renal and urinary disorders | 1.2% (165 of 14,244) | 1.3% | 8 |
| Hyperlipidaemia | Metabolism and nutrition disorders | 14.1% (162 of 1,151) | 4.8% | 3 |
| Atrial fibrillation | Cardiac disorders | 1.0% (155 of 15,686) | 1.2% | 11 |
| Blood creatinine increased | Investigations | 1.2% (146 of 12,487) | 0.0% | 4 |
| Weight decreased | Investigations | 1.0% (142 of 13,872) | 0.1% | 11 |
| Fall | Injury, poisoning and procedural complications | 0.9% (142 of 15,672) | 2.5% | 8 |
| Lipase increased | Investigations | 3.0% (132 of 4,393) | 3.4% | 10 |
| Cardiac failure | Cardiac disorders | 0.9% (121 of 14,023) | 2.1% | 6 |
| Angina unstable | Cardiac disorders | 0.8% (109 of 13,677) | 1.1% | 8 |
| Angina pectoris | Cardiac disorders | 0.7% (108 of 15,976) | 1.2% | 10 |
| Cellulitis | Infections and infestations | 0.7% (90 of 13,426) | 0.9% | 8 |
| Coronary artery disease | Cardiac disorders | 0.6% (89 of 14,676) | 1.1% | 8 |
| Pyrexia | General disorders | 0.6% (86 of 14,133) | 0.2% | 10 |
| Peripheral arterial occlusive disease | Vascular disorders | 0.7% (86 of 13,216) | 0.5% | 6 |
| Sepsis | Infections and infestations | 0.6% (85 of 14,997) | 0.7% | 7 |
| Abdominal distension | Gastrointestinal disorders | 3.6% (84 of 2,350) | 2.3% | 10 |
| Abdominal discomfort | Gastrointestinal disorders | 1.1% (82 of 7,434) | 0.2% | 10 |
| Syncope | Nervous system disorders | 0.6% (81 of 14,259) | 0.7% | 6 |
| Cholecystitis acute | Hepatobiliary disorders | 0.5% (79 of 15,361) | 0.3% | 9 |
| Cholelithiasis | Hepatobiliary disorders | 0.5% (78 of 16,464) | 1.0% | 11 |
| Cardiac failure chronic | Cardiac disorders | 0.6% (77 of 12,105) | 0.4% | 3 |
| Gastroenteritis | Infections and infestations | 0.5% (75 of 16,364) | 0.3% | 12 |
| Covid-19 pneumonia | Infections and infestations | 0.9% (70 of 7,392) | - | 3 |
| Acute myocardial infarction | Cardiac disorders | 0.5% (69 of 14,860) | 1.1% | 8 |
| Anaemia | Blood and lymphatic system disorders | 0.4% (67 of 15,427) | 0.5% | 10 |
| Diabetic foot | Skin and subcutaneous tissue disorders | 0.6% (67 of 11,972) | 0.4% | 3 |
| Abdominal pain | Gastrointestinal disorders | 0.4% (66 of 17,050) | 0.3% | 16 |
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.7% (59 of 9,034) | 1.2% | 7 |
| Cardiac failure congestive | Cardiac disorders | 0.4% (59 of 14,446) | 0.9% | 6 |
| Non-cardiac chest pain | General disorders | 0.4% (53 of 14,562) | 0.7% | 6 |
| Abdominal pain upper | Gastrointestinal disorders | 0.3% (52 of 15,891) | 0.3% | 13 |
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | 0.4% (52 of 14,235) | 0.7% | 6 |
| Dyslipidaemia | Metabolism and nutrition disorders | 2.5% (49 of 1,923) | 2.0% | 5 |
| Septic shock | Infections and infestations | 0.4% (48 of 11,590) | 0.4% | 2 |
| Acute coronary syndrome | Cardiac disorders | 0.4% (46 of 11,972) | 0.8% | 3 |
| Nephrolithiasis | Renal and urinary disorders | 0.3% (45 of 15,642) | 0.4% | 9 |
| Urosepsis | Infections and infestations | 0.4% (45 of 11,644) | 0.4% | 3 |
| Myocardial infarction | Cardiac disorders | 0.3% (44 of 15,898) | 0.7% | 11 |
| Osteomyelitis | Infections and infestations | 0.3% (44 of 14,704) | 0.2% | 7 |
| Gastritis | Gastrointestinal disorders | 0.3% (43 of 14,054) | 0.4% | 9 |
| Dehydration | Metabolism and nutrition disorders | 0.3% (42 of 13,667) | 0.3% | 8 |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | 0.3% (41 of 12,772) | 0.4% | 5 |
| Glomerular filtration rate decreased | Investigations | 0.3% (40 of 12,158) | 0.0% | 4 |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | 0.3% (40 of 12,174) | 0.4% | 4 |
| Fatigue | General disorders | 0.3% (39 of 14,198) | 0.2% | 13 |
| Diabetic nephropathy | Renal and urinary disorders | 0.3% (39 of 13,672) | 0.5% | 8 |
| Pancreatitis acute | Gastrointestinal disorders | 0.3% (38 of 14,562) | 0.2% | 8 |
| Transient ischaemic attack | Nervous system disorders | 0.3% (38 of 13,183) | 0.5% | 7 |
| Hyperkalaemia | Metabolism and nutrition disorders | 0.3% (38 of 12,558) | 0.2% | 4 |
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | 0.3% (38 of 14,030) | 0.3% | 4 |
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | 0.2% (37 of 15,932) | 0.4% | 9 |
| Myocardial ischaemia | Cardiac disorders | 0.2% (36 of 14,821) | 0.5% | 6 |
| Inguinal hernia | Gastrointestinal disorders | 0.3% (36 of 13,076) | 0.2% | 6 |
| Chronic kidney disease | Renal and urinary disorders | 0.3% (36 of 12,673) | 0.4% | 5 |
| Gangrene | Infections and infestations | 0.3% (36 of 11,892) | 0.2% | 3 |
| Decreased Appetite | Metabolism and nutrition disorders | 11.9% (36 of 302) | - | 1 |
| Chest pain | General disorders | 0.3% (35 of 13,868) | 0.3% | 8 |
| Cholecystitis | Hepatobiliary disorders | 0.3% (35 of 13,295) | 0.3% | 7 |
| Cerebrovascular accident | Nervous system disorders | 0.2% (35 of 14,783) | 0.6% | 7 |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 0.3% (34 of 12,950) | 0.3% | 7 |
| Amylase increased | Investigations | 0.2% (33 of 15,238) | 0.0% | 8 |
| Ankle fracture | Injury, poisoning and procedural complications | 0.3% (33 of 12,717) | 0.4% | 5 |
| Spinal osteoarthritis | Musculoskeletal and connective tissue disorders | 0.2% (32 of 13,388) | 0.4% | 7 |
| Erysipelas | Infections and infestations | 0.3% (32 of 12,388) | 0.3% | 4 |
| Femur fracture | Injury, poisoning and procedural complications | 0.3% (32 of 12,188) | 0.4% | 3 |
| Injection site reaction | General disorders | 2.9% (31 of 1,075) | 0.0% | 4 |
| Adenocarcinoma of colon | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.3% (31 of 11,590) | 0.3% | 2 |
| Atrioventricular block second degree | Cardiac disorders | 0.2% (30 of 13,733) | 0.2% | 5 |
| Hip fracture | Injury, poisoning and procedural complications | 0.3% (30 of 11,873) | 0.3% | 3 |
| Gastrointestinal haemorrhage | Gastrointestinal disorders | 0.2% (29 of 12,305) | 0.3% | 5 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
FDA LABEL
What the FDA label says
Trulicity BLA125469 · label of 2026-06-16 Regulator
Most common adverse reactions (incidence ≥5%) are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.
QUESTIONS
Does dulaglutide cause nausea?
In 11 placebo-controlled trials with posted results, 14.5% of people on dulaglutide reported nausea, against 5.5% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does dulaglutide cause diarrhoea?
In 11 placebo-controlled trials with posted results, 12.8% of people on dulaglutide reported diarrhoea, against 8.5% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does dulaglutide cause nasopharyngitis?
In 11 placebo-controlled trials with posted results, 11.2% of people on dulaglutide reported nasopharyngitis, against 10.4% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does dulaglutide cause urinary tract infection?
In 11 placebo-controlled trials with posted results, 10.2% of people on dulaglutide reported urinary tract infection, against 9.8% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does dulaglutide cause back pain?
In 11 placebo-controlled trials with posted results, 8.4% of people on dulaglutide reported back pain, against 7.9% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
REGISTERED STUDIES
144 registered clinical trials of Dulaglutide
The 10 most recently updated are listed.
| NCT07668336 | A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes Status: NOT_YET_RECRUITING · Updated 2026-09-25 |
|---|---|
| 2025-524811-35-00 | J2A-MC-GZGY: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Status: UNKNOWN · Updated 2026-09-24 |
| NCT07834398 | Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes Status: COMPLETED · Updated 2026-09-22 |
| NCT06779929 | Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes Status: COMPLETED · Updated 2026-09-18 |
| NCT07820111 | Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Status: COMPLETED · Updated 2026-09-15 |
| NCT06851962 | Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. Status: COMPLETED · Updated 2026-09-04 |
| NCT07787936 | GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry Status: NOT_YET_RECRUITING · Updated 2026-08-26 |
| NCT07313813 | A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus Status: COMPLETED · Updated 2026-08-21 |
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study Status: ACTIVE_NOT_RECRUITING · Updated 2026-08-13 |
| NCT05478707 | Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes Status: RECRUITING · Updated 2026-08-12 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.